What is Inflow?
Inflow offers a science-based program designed to help individuals manage Attention Deficit Hyperactivity Disorder (ADHD). Developed by a team of clinicians and coaches, many of whom personally navigate ADHD, the company provides an affordable and accessible solution. Leveraging the principles of Cognitive Behavioral Therapy (CBT), Inflow equips users with daily exercises, challenges, and tools to implement effective strategies at their own pace, fostering significant positive changes in everyday life. The company operates within the burgeoning digital health and wellness sector, specifically targeting the underserved market of ADHD management solutions.
How much funding has Inflow raised?
Inflow has raised a total of $13.3M across 2 funding rounds:
Angel/Seed
$2.3M
Series A
$11M
Angel/Seed (2022): $2.3M with participation from Route 66 Ventures, Hoxton Ventures, Maroof Ahmed, and Yusuf Sherwani
Series A (2023): $11M led by Octopus Ventures, Route 66 Ventures, and Hoxton Ventures
Key Investors in Inflow
Octopus Ventures
Octopus Ventures is a founder-focused venture capital firm that backs mission-driven companies across software, climate, health, consumer, and financial technology, offering long-term capital and guidance.
Route 66 Ventures
Route 66 Ventures is a private investment firm specializing in venture capital and credit solutions for emerging financial technology and services companies, with a global focus on early and growth-stage disruptors.
Hoxton Ventures
Hoxton Ventures is an early-stage venture capital firm based in London, investing in European technology startups with the potential for global scale, focusing on disruptive or category-inventing companies.
What's next for Inflow?
With the recent major strategic investment, Inflow is poised for significant expansion and enhancement of its ADHD management platform. The substantial enterprise-level funding suggests a strategic focus on scaling operations, further developing its science-based program, and potentially broadening its market reach. This capital infusion will likely enable Inflow to deepen its clinical research, enhance user engagement features, and solidify its position as a leader in digital therapeutics for ADHD. The company's trajectory indicates a strong commitment to innovation and growth within the health technology landscape.
See full Inflow company page
